Fundraising Fox
Foresite Capital
Venture capitalWest Hollywood · Seed–Late Stage · 44 people tracked
Also known as FORESITE CAPITAL MANAGEMENT, LLC
Find your way into Foresite Capital
Sign up to see every warm intro you have to Foresite Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Foresite Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Foresite Capital concentrates on the forces transforming healthcare, investing in people, ideas and discoveries that combine technology and biotechnology to personalize care and speed innovation and product development. The firm practices full-lifecycle investing, partnering with companies from incubation through IPO and beyond to have impact regardless of timing. Its team of investment analysts, MD/PhDs and data scientists collaborates closely with portfolio companies, drawing on operational and investment experience and an extensive healthcare network. The firm believes healthcare is undergoing unprecedented innovation fueled by growing understanding of biologic and genetic information, and aims to use its capital and networks to build transformative companies improving the U.S. healthcare system.
Source: firm website, verified Oct 13, 2026.
Team · 44 people
from the firm's website & curated & public directories
Jim Tananbaum is founder and CEO of Foresite Capital Management, a healthcare-focused investment firm based in the San Francisco Bay Area with approximately $4 billion in assets under management as of December 2021. The firm invests in healthcare companies across multiple stages and employs clinical scientists, engineers, analysts, and partners to support portfolio companies.
Dorothy Margolskee joined Foresite Capital in 2012, where she has overseen the firm's research and development evaluation group and built an early version of its investment technical review process for analyzing biotechnology portfolios. She previously served as Managing Director in charge of Research at Prospect Ventures, and earlier spent 15 years in drug development at Merck Research Labs, rising to Senior Vice President and contributing to programs including several vaccines and HIV treatments. She holds an M.D. from Johns Hopkins Medical School and a B.A. from Harvard University, and is board certified in Internal Medicine and Pulmonary.
Hadi Tabbaa is a Managing Director at Foresite Capital, working in alternative asset management. His areas of focus include capital raising, investor relations, business development, sales, and mergers and acquisitions.
Hyung Chun is a physician scientist who joined Foresite Capital in 2021, where he evaluates investment opportunities in private and public biotech companies. Before Foresite, he was a tenured faculty member at Yale School of Medicine, where he held roles including Co-Director of the Yale Cardiovascular Research Center, and remains an adjunct faculty member. He earned an A.B. in Biochemical Sciences from Harvard College and an M.D. from Johns Hopkins, and completed his residency and cardiovascular fellowship at Stanford.
Shannon Bergstedt is a member of the Investment Team at Foresite Capital, where she focuses on life sciences and healthcare technology. She previously spent six years at Verily (formerly Google Life Sciences) as a Business Development Lead, was on the founding team of Evidation Health, and held roles at GE Ventures, Kleiner Perkins, and CardioDx. She holds Bachelor's and Master's degrees from Stanford University and an MBA from Harvard Business School.
Stephen Peterson is a Managing Director at Foresite Capital Management, where he identifies and evaluates investment opportunities in healthcare technology and services. He joined the firm in 2011 as its second investment team member and serves on its investment and valuation committees, along with holding board positions at Sollis Health and board observer roles at Thyme Care, Signant Health, and ConnectiveRx. Peterson previously worked as an equity analyst at Palo Alto Investors and Wells Fargo, holds the CFA Charter, and has lectured on investment analysis and financial modeling at multiple universities.
Deepak Atri joined Foresite Capital in 2022 as part of the investment team, where he evaluates opportunities in biotech and healthcare companies. A physician-scientist, he earned his MD at Yale as a Howard Hughes Medical Institute research fellow, and completed clinical training in medicine at The Johns Hopkins Hospital and cardiovascular medicine at Brigham & Women's Hospital. He also did a postdoctoral fellowship in molecular and population genetics with Brigham & Women's and The Broad Institute of MIT & Harvard.
Luke Bagaason joined Foresite Capital in 2014 as an analyst and currently serves as Manager of Portfolio Valuation, overseeing monitoring of the firm's privately held investment portfolio. Before Foresite, he operated his own registered investment advisory providing asset management and consulting to investment firms and individuals, and previously worked at JP Morgan Asset Management starting in 2007. He earned the CFA designation in 2013.
Vishal Deshmukh is a member of the investment team at Foresite Capital, where he evaluates investment opportunities in biotech companies. He previously served as Director of Discovery Biology at Kinnate Biopharma, leading early discovery and development of small molecule oncology therapeutics, and as Director of Biology at Biosplice Therapeutics, where he managed programs across oncology, musculoskeletal, and dermatology areas. Earlier he was a Visiting Scientist at Calibr and the Genomics Institute of the Novartis Research Foundation, and he holds a Ph.D. in Biology from The Scripps Research Institute, an M.S. in Biotechnology from UC Irvine, and a B.S. in Pharmaceutical Sciences from the Institute of Chemical Technology, Mumbai.
Uplaksh Kumar is a venture partner at Foresite Capital. He previously served as SVP of strategic operations and scale at GRAIL, where he launched the Galleri multi-cancer early detection test, and was the first head of operations at Verily. He has held leadership roles at Life Technologies, BD, LONZA, and Qiagen, and co-founded RoosterBio, a regenerative medicine company focused on research and clinical-grade stem cells.
Alex Azar served as the 24th Secretary of the U.S. Department of Health and Human Services from 2018 to 2021, overseeing a workforce of more than 85,000 and a budget exceeding $1.4 trillion. In that role he oversaw Operation Warp Speed to develop COVID-19 vaccines and therapeutics, and led initiatives on drug pricing, telehealth expansion, health record interoperability, the opioid crisis, and global health security. He has held senior roles in both U.S. government and the private sector, focused on healthcare.
Cynthia Carpenter supports the office of the CEO at Foresite Capital. She has over two decades of experience assisting C-level executives, including a prior role supporting Jim Tananbaum at Prospect Venture Partners and serving as an executive assistant to the co-founder at CKS Partners.
Darren Haggerty handles the review and reconciliation of the firm's private and public holdings and records associated trading activity. He is an operations and finance professional with more than 20 years of experience in private equity, and previously served as director of operations for Lighthouse Capital. He also has consulting experience.
Insiya Essani is a member of the investment team at Foresite Capital, where she focuses on therapeutics investment opportunities. She previously worked as a Life Science Consultant at ClearView Healthcare Partners on strategic and due diligence projects for pharma, biotech, and life sciences clients, and held earlier roles at Barclays and Bristol Myers Squibb. She holds a B.A. in Chemistry from Princeton University.
Jacqueline Guttman joined Foresite Capital in 2021 as an Associate Director on the Investor Relations team, where she supports the firm's existing limited partners and manages communications, external events, and content development. She previously spent nearly five years on the investments team at the Carnegie Corporation of New York and worked as an analyst at TD Securities. She holds a Bachelor of Arts in Economics from Barnard College, Columbia University.
Jody Dutton joined Foresite Capital in 2012 as an early member of the administrative team and provides executive support to the investment team. Before joining the firm, she worked for 10 years as an executive assistant to the President of Food & Beverage at a casino in Northern California, where she handled travel, meetings, and menu planning and design and assisted with two expansions.
Jorge Campos is a member of Foresite Capital's compliance team, where he helps develop, implement, and maintain the firm's compliance program. He has around eight years of experience in compliance, previously serving as Senior Compliance Associate at CVC Credit Partners and earlier working at the compliance consultancy Cordium.
Kara Govi supports the office of the CEO at Foresite Capital. Her background includes senior executive assistant roles across venture capital, startups, and executive search. She holds a degree in Advertising with a minor in Personality and Social Psychology from San Diego State University.
Kelly Ashauer joined Foresite Capital in 2018, where she provides executive support to the investment team and Investor Relations leadership. Before Foresite, she held roles in the Education and Training office of the Department of Medicine at Memorial Sloan Kettering Cancer Center, most recently supporting the Transitional Year Residency Program. She holds a B.A. in Business Communications from Rockhurst University in Kansas City, MO.
Kevin Kelly joined Foresite Capital in 2018 as a member of the investment team, working on trading that is cost effective and compliant. He has over 20 years of experience in institutional asset management with a focus on SMID Cap trading, operations, and investment process optimization, having previously served as head trader and vice president of operations at RS Investments and beginning his career at Putnam Investments in international trade support. He holds a B.A. from Connecticut College with a concentration in political economies.
Lisa Klyse is an administrative professional with more than 20 years of experience supporting executives across various industries. She joined Foresite Capital in 2019 to support the operations team and the Chief Financial Officer, having previously worked in institutional equity sales supporting sales and trading executives. She holds a B.S. in Hospitality Management from the University of Nevada, Las Vegas.
Liz Canis is an executive advisor at Foresite Capital Management, where she sources opportunities, oversees diligence, monitors portfolio assets, and supports internal incubation efforts. She previously served as vice president of emerging business and partnerships at Elevance Health, ventures lead at healthcare venture firm Savvysherpa, and founder and CEO of The Pivot Group. Earlier she spent eleven years in leadership roles at UnitedHealth Group. She holds a BA from Northwestern University and an MBA from the University of Michigan Ross School of Business.
Mathai Mammen has advised Foresite Capital since 2019 and is Chairman and CEO of Parabilis Medicines (formerly FogPharma). He previously served on the Executive Committee of Johnson & Johnson as EVP of J&J Pharmaceuticals R&D and was senior vice president at Merck Research Laboratories, leading research across cardiovascular, metabolic, renal, oncology/immuno-oncology and immunology areas. Earlier he co-founded and led R&D at Theravance, which he built on science from his PhD at Harvard University, and spun out Innoviva and Theravance Biopharma.
Max Lien joined Foresite Capital in 2023, where he handles investor relations and business development. He previously served as VP of Business & Corporate Development at Hyperscience, an enterprise AI company, where he built the team globally and established partnerships with firms including McKinsey, IBM, and AWS. Earlier in his career, he worked on strategy and corporate/business development teams at Bloomberg and BlackRock, focusing on M&A, partnerships, and growth across financial services, software, and AI.
Nicole McCann joined Foresite Capital in 2011, where she supports the administrative team with functions ranging from data entry to process development. She previously held business office roles at Ford on the operations team, working with accounting, human resources, and payroll. She holds an AA with an Accounting concentration from Liberty University and is pursuing a B.S. in Accounting and Business Administration.
Richard Lau joined Foresite Capital in 2014, where he works on the investment team handling due diligence and financial modeling of potential investments. He previously served as an equity research analyst covering specialty pharmaceuticals at Wedbush PacGrow Life Sciences and began his career at Pacific Growth Equities, rising from equity research associate to senior analyst covering biotechnology. He holds a B.A. in Molecular and Cell Biology with a biochemistry concentration from UC Berkeley and is a CFA Charterholder.
Robert (Bob) Gunderson is the founding partner and now Chairman Emeritus of Gunderson Dettmer, an international law firm serving emerging growth companies and venture capital and growth equity investors. Over four decades he advised parties in venture financings, IPOs, M&A and fund formations. He co-edited a text on venture capital and public offering negotiation, is a fellow of the American College of Governance Counsel and the American Bar Foundation, and has served as a director of several public companies.
Rowena Dayanghirang supports fund transactions and legal matters at Foresite Capital. Before joining the firm, she spent over five years as a Corporate Paralegal at Gunderson Dettmer, LLP, handling corporate and transactional work for private companies across various industries. She previously worked as a Corporate Paralegal Assistant at Perkins Coie, LLP for two years.
Susan Gatrill joined Foresite Capital's accounting team in 2015, where she handles review, reconciliation, and analysis of fund financial activity along with quarterly reporting. She has close to 20 years of experience in venture capital accounting, including 13 years as a fund accountant and later senior accountant at Lighthouse Capital Partners, a venture debt firm, where she managed daily operations and monthly and quarterly close for multiple investment funds.
Tiffany Bond handles day-to-day accounting for Foresite Capital's entities, including accounts payable and receivable, capital call and cash distribution processing, and daily cash management. She joined the firm in November 2014. Before that, she was the office and technology manager at Kreuzberger|Associates, a finance and accounting recruiting firm in the San Francisco Bay Area.
Founder mafia
4 people who came through Foresite Capital went on to found or lead other companies.
What they invest in
from 188 of 241 portfolio companiesBiotech ×145Healthtech ×112Medical Devices ×63Digital Health ×39AI & Machine Learning ×35Deep Tech ×22Enterprise Software ×14SaaS ×9
HQs:United States×136United Kingdom×5France×2Canada×1China×1Denmark×1
Who they back
founder profiles across 95 portfolio companiesFounding team size:solo founder×342 founders×303 founders×154+ founders×16
Where their founders studiedfrom 79 founders with education data
Stanford University ×7Harvard University ×6Massachusetts Institute of Technology ×4University of California, Berkeley ×4Brown University ×3The Wharton School ×3University of Pennsylvania ×3American University of Beirut ×2
What their founders studiedfrom 81 founders with field-of-study data
Life Sciences ×31Chemistry ×14Engineering ×12Computer Science ×10Business & Management ×9Medicine ×8Physics ×5Economics ×4
Where their founders worked beforefrom 81 founders with career history
Stanford University ×7Harvard Medical School ×3OrbiMed ×3Third Rock Ventures ×3University of California, Berkeley ×3AstraZeneca ×2Atlas Venture ×2Exelixis ×2
Accelerator rootsportfolio companies that came through a program
51 founders hold a PhD · 13 hold an MBA (of 84 with degree data)
Investments · 241 tracked
founders shown can be your intro pathBy year:2026 · 62025 · 72024 · 132023 · 22022 · 82021 · 152020 · 72019 · 52018 · 62017 · 42016 · 52015 · 894 dated
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Board seatJames Tananbaum· per SEC Form D
Co-investorsGeneral AtlanticHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMedSamsara BioCapital+4 more
Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.
BiotechCambridge, US
Robert Gould(Executive Officer, Director)inAlex C. Sapir(President and Chief Executive Officer, Director)in
BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)
Board seatJames Tananbaum· per SEC Form D
Co-investorsSanofi VenturesThird Rock Ventures
10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers.
BiotechDeep TechHardwareHealthtechPleasanton, US
Serge Saxonov(Founder)inBen Hindson(Founder)inBrad Crutchfield(Chief Commercial Officer)inJean Philibert(Chief People Officer)Eric S Whitaker(General Counsel)inJustin McAnear(Chief Financial Officer)in
Co-investorsFoothill VenturesKhosla VenturesOMX VenturesPaladin Capital GroupSoftBank Vision FundVenrock+4 more
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalRA CapitalSofinnova VenturesSofinnova Venture Partners+1 more
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US
James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in
Co-investorsAvoro Capital AdvisorsEight Roads VenturesF-Prime CapitalNew Enterprise Associates (NEA)Ridgeback Capital
Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US
Chad Robins(Chief Executive Officer, Co-founder, Chairman of the Board)inHarlan Robins(Co-founder; Chief Scientific Officer until 2026)inKathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)Kyle Piskel(Chief Financial Officer)in
Co-investorsDecheng CapitalFMG CapitalKhosla VenturesViking GlobalCasdin CapitalOrbiMed
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in
BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)
Co-investorsOrbiMedPontifax Venture CapitalQuan CapitalaMoonNovartis Venture FundPureTech Health
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsGV (Google Ventures)Mission Bay CapitalMission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsAvoro Capital AdvisorsTPGVida VenturesGilead Sciences
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1HBM Healthcare InvestmentsHBM PartnersvenBio PartnersLogos+1 more
Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.
BiotechHealthtechWarminster, US
William H. Collier(President and Chief Executive Officer)inGaston Picchio(Chief Development Officer)inMichael J. McElhaugh(Chief Business Officer)inDavid C. Hastings(Chief Financial Officer)inMichael J. Sofia(Chief Scientific Officer)inElizabeth Howard(Executive Officer)in
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesJazzya InvestmentsMedicxi+6 more
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder)inJ. Keith Joung(Founder)inFeng Zhang(Founder)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalGV (Google Ventures)HongShan Capital Group+2 more
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.
Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalPremji InvestRA CapitalRed Tree Venture+6 more
CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells.
BiotechHealthtechBeijing
Chunhua Wang(Chief Operating Officer)Wei Gao(General Counsel)Hai Huang(Global Chief Commercial Officer)Alexander A. Zukiwski(Chief Medical Officer)Wei (Larry) Zhang(President)Wei-Wu He(Chief Executive Officer, Chairman of the Board of Directors)
Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.
BiotechHealthtechHampton, US
Anthony S. Marucci(Executive Officer, Director)inAvery W. Catlin(Executive Officer)
BoardRichard van den Broek(Director)Timothy M. Shannon, M. D.(Director)Herbert J. Conrad(Director)Karen Shoos(Director)
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+3 more
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Co-investorsAlumni VenturesBioBritF-Prime CapitalGV (Google Ventures)OrbiMedvenBio Partners+3 more
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
BiotechSan Diego, US
Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)
Co-investors5AM VenturesOrbiMedRA CapitalVivo Capital
Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.
BiotechHealthtechMedical Devices
Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNadim Ahmed(President and Chief Executive Officer)in
Co-investorsNextech InvestBiotechnology Value FundOrbiMed
Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
James SpudichinRonald ValeLawrence S.B. GoldsteinRobert I. Blum(President and Chief Executive Officer)in
BoardJames Sabry
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)
Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalGV (Google Ventures)Flagship PioneeringFlagship Ventures
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesFrazier Life SciencesOrbiMed5AM Ventures+7 more
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
BiotechDigital HealthBoulder, US
Kevin Koch(Executive Officer, Director)inAlan Russell(Director)inBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)
BoardPeter Thompson(Director)inJonathan Root(Director)in
Co-investorsBoulder VenturesOrbiMedUS Venture PartnersViking GlobalWellington ManagementDeerfield Management Company+1 more
A pharmaceutical company whose executive team emphasizes innovation and patient care.
BiotechDigital HealthMental Health
Co-investorsRA Capital
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more
-2.png)
Hinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions.
Digital HealthHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Gabriel Mecklenburg(Founder)inDaniel Perez(Founder)inKevin McCullough(Founder)Shaun Rahimi(Founder)
Co-investors11.2 CapitalAlkeon InnovationAtomicoBessemer Venture PartnersCannage CapitalCoatue Management+16 more
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)inS. Nicole Schaeffer(Chief People Strategy Officer)in
Co-investorsBessemer Venture PartnersF-Prime CapitalHercules Capital, Inc.OrbiMedProspect Venture PartnersRidgeback Capital+1 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 CapitalOrbiMedRidgeback Capital+1 more
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in
Co-investorsBain Capital Life SciencesGV (Google Ventures)MRL Ventures FundPremji InvestRA CapitalFidelity Investments+6 more
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.
BiotechHealthtechLexington, US
Jasbir Seehra(Co-Founder, Chief Executive Officer and Director)in
BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in
Co-investorsArkin CapitalOrbiMedPontifax Venture Capital
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
PINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalNextech InvestOUP (Osage University Partners)
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in
Co-investorsAvoro Capital AdvisorsBay City Capital
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.Alexandria+9 more
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesHarmony PartnersHBM Healthcare InvestmentsLightspeed Venture Partners+4 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesLightspeed Venture PartnersRA CapitalWellington ManagementBiotechnology Value Fund+2 more
Omeros is a publicly traded biotech company developing a diverse pipeline of first-in-class small-molecule and antibody therapeutics targeting unmet medical needs across multiple therapeutic areas and indications.
BiotechHealthtechMedical DevicesSeattle, US
Co-investorsSPRINGROCK VENTURES
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPDeerfield Management CompanyFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases.
BiotechSouth San Francisco, US
Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)inBrendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)inKristen Gafric(Executive Officer)
Co-investorsSofinnova PartnersTakeda Ventures
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesEcoR1 CapitalNat TurnerNextech InvestSoftBank Vision FundCurie.Bio+2 more
Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.
BiotechHealthtechMedical Devices
Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)
Co-investorsAtlas VentureBain Capital Life SciencesREDMILE
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical DevicesRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Co-investorsBain Capital Life SciencesGen CapitalGV (Google Ventures)Illinois VenturesNextech InvestThe Column Group+2 more
RxSight is an ophthalmic medical technology company that developed the Light Adjustable Lens (LAL), an intraocular lens that can be customized after cataract surgery to optimize a patient's vision.
HardwareHealthtechMedical DevicesPasadena, US
Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(Chief Medical Officer (former President & CEO))Mark Wilterding(Chief Financial Officer)in
Co-investorsFlying L PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalRA CapitalVisionary Ventures+2 more
SCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments.
BiotechMedical DevicesDurham, US
Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDavid Angulo(President & Chief Executive Officer)inEric Sukenick(General Counsel)Sanjay Subramanian(Chief Financial Officer)
Co-investorsDecheng CapitalDeerfield Management CompanyRA Capital
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in
Co-investorsARCH Venture PartnersGeneral AtlanticHAWKTAILPureTech HealthSofinnova VenturesCPP Investments+4 more
Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
BiotechLondon
Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)
BoardJames Ede-Golightly(Director)Alistair Gray(Director)
Co-investorsMC Healthcare VenturesNextech InvestVivo Capital
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.
BiotechHealthtechCharlestown, US
Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)
Co-investorsBain Capital Life SciencesRA CapitalBain Capital
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Frazier Life SciencesJanus Henderson InvestorsLongitude CapitalMedicxi+4 more
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
Alan Huang(Executive Officer)inAdam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)
BoardBarbara Weber(Executive Officer, Director)in
Co-investorsNextech InvestNSG VenturesRoche Venture FundThird Rock Ventures
Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates.
BiotechHealthtech
Grant Pickering(Chief Executive Officer, Director and Co-Founder)inJeff Fairman(Vice President of Research and Co-Founder)
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Frazier Life SciencesLongitude CapitalPivotal Life SciencesRA Capital+3 more
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersLightstone VenturesLongwood FundOberland CapitalViking Global+1 more
Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.
BiotechHealthtechLongevitySingapore, US
Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)inPaul Bolno, MD, MBA(President and Chief Executive Officer, Wave Life Sciences)
BoardPeter Kolchinsky(Director)inKen Takanashi(Director)
Co-investorsRA CapitalAescap Life Sciences
Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.
BiotechHealthtech
Ian Mortimer(President and Chief Executive Officer)inDarren Cline(Chief Commercial Officer)inAndrea DiFabio(Chief Legal Officer and Corporate Secretary)inJames Empfield(Executive Vice President, Drug Discovery)inTucker Kelly(Chief Financial Officer)inChris Kenney(Chief Medical Officer)in
Co-investorsArcher Capital GroupArcher Venture CapitalAvoro Capital AdvisorsNew Enterprise Associates (NEA)
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Board seatMichael Rome· per SEC Form D
Co-investorsAtlas VentureThe Column GroupARCH Venture PartnersAlexandriaDecheng Capital
bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.
BiotechDeep TechHealthtechMedical Devices
Dr Mark Kotter(Founder)Przemek Obloj(CEO)inEmma Pepperell(CEO)inMark Kotter(Founder)
Co-investorsBlueYard CapitalARCH Venture PartnersDynamk CapitalGood AI CapitalHarmonix FundHAWKTAIL+8 more
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsDementia Discovery FundGV (Google Ventures)SV Life SciencesDementia DiscoveryDolby Family VenturesLightstone Ventures+4 more
HealthVerity operates a healthcare and consumer data ecosystem that enables HIPAA-compliant synchronization and exchange of real-world data across pharma, payers, and government agencies.
Data & InfrastructureEnterprise SoftwareHealthtechPhiladelphia, US
Andrew Kress(Co-Founder and CEO)inAndrew Goldberg(Co-Founder and COO)
BoardMichael Greeley(Director)inRachel Winokur(Director)
Co-investorsFlare Capital PartnersGreycroftNew Enterprise Associates (NEA)
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsLongwood FundNorwest Venture PartnersPivotal Life SciencesRiverVest Venture PartnersYsios Capitalabrdn plc+4 more
Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.
BiotechHardwareHealthtech
Co-investorsMedical Excellence CapitalDeerfield Management Company
Spear Bio develops high-sensitivity immunoassays based on its SPEAR (Successive Proximity Extension Amplification Reaction) technology, which originated from research at the Wyss Institute.
BiotechHealthtechMedical Devices
Feng Xuan(Chief Executive Officer & Co-founder)Peng Yin(Director & Co-Founder)
Co-investorsMaverick VenturesYonghua Capital
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)
Board seatMichael Rome· per SEC Form D
Co-investorsNextech InvestViking GlobalJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors
Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.
BiotechHealthtechSan Francisco, US
Uri Lopatin(CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)inElizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)
BoardJ. Jay Lobell(Director)
Board seatJames B. Tananbaum· per SEC Form D
Co-investorsFrazier Life SciencesY CombinatorKhosla Ventures
Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.
BiotechHayward, US
Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in
BoardJoshua Wolfe(Director)inDror Berman(Director)Leon Chen(Director)
Board seatJames Tananbaum· per SEC Form D
Co-investorsBain Capital Life SciencesCisco InvestmentsLux CapitalDimension Capital
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Eric Bednarski(Director)Derek Ferguson(Director)
Board seatJames Tananbaum· per SEC Form D
Co-investorsMVM Life Science PartnersOxford Finance LLCQuaker BioVentures
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inCarl Gordon(Director)in
Board seatMichael Rome· per SEC Form D
Co-investorsLongitude CapitalNextech InvestNexTech VenturesOmega FundsOrbiMedPontifax Venture Capital+2 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+9 more
A pharmaceutical company that develops medicines and vaccines for patients globally.
BiotechHealthtechMedical DevicesCambridge, US
WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMATTHEW L. SHERMAN(Executive Officer)
Co-investorsBessemer Venture PartnersLightstone VenturesLowercarbon CapitalSofinnova VenturesVenrockCollaborative Fund
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersAvoro Capital AdvisorsOUP (Osage University Partners)Sofinnova Ventures
Healthcare technology company delivering real-world evidence for life sciences companies, payers, and regulators.
Data & InfrastructureDigital HealthHealthtechNew York, US
Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Founder)Kyle Armbrester(Chief Executive Officer)inSebastian Schneeweiss(Founder)
Co-investorsB Capital GroupB4 CapitalBlue LionBlue Lion GlobalFlare Capital PartnersLG Technology Ventures+8 more
.jpeg){kind=logo}
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.
BiotechMedical DevicesCambridge, US
Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in
BoardRobert More(Director)Frances Heller(Director)George Siber(Director)
Co-investorsBain Capital Life SciencesEcoR1 CapitalViking GlobalBain CapitalRock Springs CapitalT. Rowe Price
Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
Co-investorsAisling CapitalLongitude CapitalMenlo Ventures
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureFrazier Life SciencesGeneral AtlanticLifeSci Venture PartnersScion Life SciencesThe Innovation Space+2 more
Acceldata provides a unified platform for building, governing, and scaling data and AI workloads with end-to-end observability across pipelines.
AI & Machine LearningData & InfrastructureEnterprise SoftwarePalo Alto, US
Rohit Choudhary(Founder)inAshwin Rajeeva(Founder)inSatish Krishnamurthy(Executive Officer, Director)Maram Nagendraprasad(Executive Officer, Director)Gaurav Nagar(Founder)in
BoardDev Khare(Director)in
Co-investorsDrive CapitalEMERGENT VENTURESFelicis VenturesFocal VenturesGeneral CatalystInsight Partners+23 more
Ambit Biosciences was a San Diego biopharmaceutical company developing small-molecule kinase inhibitors, including quizartinib, a FLT3 inhibitor for acute myeloid leukemia.
Co-investorsAisling Capital
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFelix JahnFJ LabsKfW CapitalQuery Capital+5 more
Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.
BiotechHealthtech
Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalGV (Google Ventures)SLVC+4 more
Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.
BiotechFremont, US
Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)inDavid Rosenbaum(Executive Officer)inJeremy Caldwell(Executive Officer)Mike Raab(Executive Officer, Director)in
BoardDavid Mott(Director)
Co-investorsHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital GroupLAV+4 more
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsRA CapitalSofinnova PartnersSofinnova Ventures
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+6 more
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.
BiotechHealthtechCambridge, US
Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in
BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)
Co-investorsF-Prime CapitalNextech InvestRA CapitalRidgeback CapitalRoche Venture FundWellington Management+1 more
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Neil Kumar(Founder)
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSLongwood Fund+2 more
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio Partners+2 more
CareGuide operates online marketplaces that connect people seeking care services with qualified caregivers across various verticals including pet care, home services, and childcare.
ConsumerDigital HealthHealthtechHR TechMarketplacesSaaSToronto, US
John GreeninAli Dinani(Chief Executive Officer)inKen Scott(Chief Financial Officer)inEmir Hasanbegovic(Chief Technology Officer)in
BoardJesse Rasch
Co-investors500 GlobalGarage CapitalInovia CapitalStructure CapitalFJ LabsOnStartups+1 more
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalGeneral AtlanticLifeSci Venture PartnersMedicxiOberland Capital+4 more
Chimagen Biosciences is a Shanghai-based clinical-stage biotech developing multi-specific antibody therapeutics, including T-cell and NK-cell engagers, for cancer and autoimmune diseases.
Clipdrop offers AI-powered image editing tools including background removal, object cleanup, image upscaling, and text-to-image generation.
AI & Machine LearningConsumerCreator EconomyMedia & EntertainmentSaaSParis, FR
Cyril Diagne(Founder)inJonathan Blanchet(Founder)inDamien Henry(Founder)in
Co-investorsAir Street CapitalKima VenturesSoma CapitalY CombinatorAmplify PartnersHarvard Management Company
Cogram builds AI-powered software tools for architects and engineers to automate documentation, reporting, and information retrieval from construction and architectural projects.
AI & Machine LearningConstruction TechEnterprise SoftwareFuture of WorkSaaSNew York City, US
Alexander von Boetticher(Founder)inRicardo Wölker(Founder)inFran Gonzalez(Engineering Manager)
Co-investorsCreative Destruction Lab (CDL)JovonoPioneerSoma CapitalY CombinatorAmplify Partners+8 more
Color Health operates a nationwide virtual cancer clinic delivering oncologist-led care, screening, and treatment management for employer, union, health plan, and public sector populations.
AI & Machine LearningDigital HealthHealthtechSan Francisco, US
Othman Laraki(Founder)inElad Gil(Founder)Nish Bhat(Founder)Taylor Sittler(Founder)
Co-investors8VCAliya Capital PartnersComcast VenturesCRV (Charles River Ventures)Dria VenturesGeneral Catalyst+14 more
ConnectiveRx provides hub services, patient support, and patient affordability programs that help pharmaceutical manufacturers, healthcare providers, and patients access and stay on prescribed therapies.
Digital HealthHealthtechSaaS
Co-investorsGenstarBlackstoneGenstar Capital
Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)
Co-investorsAvoro Capital AdvisorsOrbiMedRoche Venture Fund
Crossover Health operates an integrated primary care delivery model centered on member experience, using proprietary technology and care structures to expand healthcare access and accountability.
Digital HealthHealthtech
Ryan Smith
Co-investorsNorwest Venture Partners
Covid test maker that went public at a $2.3 billion valuation.
Clint Sever(Founder)in
Co-investorsACME CapitalDarwin CapitalDecheng CapitalDentsu VenturesMothership VCPrime Partners+4 more
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in
Co-investorsAvoro Capital AdvisorsBay City CapitalVantagePoint Capital PartnersAbingworth
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Co-investorsAV8 VenturesIllumina VenturesInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation FundMSD Global Health Innovation Fund+7 more
HealthtechMenlo Park, US
Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)
BoardFred Craves(Director)in
Co-investorsAisling CapitalBay City CapitalCanaan PartnersNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more
DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.
AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US
Andreas Sundquist(Founder)inSerafim Batzoglou(Founder)inRichard Daly(Executive Officer, Director)inGeorge Asimenos, PhD(Chief Product Officer)inArend Sidow(Founder)
BoardMichael Goldberg(Director)
Co-investorsClaremont Creek VenturesGV (Google Ventures)K9 VenturesSaints CapitalUncork CapitalWireframe Ventures
A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.
BiotechDigital HealthHealthtechSan Francisco, US
NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)
Co-investorsAisling CapitalRA CapitalViking GlobalViking Global Investors
Element Materials Technology provides materials testing, product qualification, and assurance services for customers in aerospace, space, defense, and energy sectors.
Advanced ManufacturingDeep TechDefense TechEnterprise SoftwareMedical DevicesNew Materials
Rick Sluiters(CEO of Element Aero, Space & Defense)
Co-investors3i GroupMetaplanetProtocol LabsT. Rowe PriceVenrock
Element is an NFT marketplace on Ethereum where users can create, swap, and trade NFT collections, with real-time floor price and volume data tracking.
Crypto & Web3Marketplaces
Co-investorsBitDAOMantle NetworkMetaplanetProtocol LabsT. Rowe PriceVenrock
Element modernizes legacy mainframe systems using its Global Context Engine, which performs deterministic analysis of a codebase to extract system infrastructure, data flows, and business logic as a foundation for modular transformation.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareParis, FR
Alexander Wiener(CEO)inLukas Marienfeld(CTO)in
Co-investorsEntrepreneur FirstProject EuropeTranspose Platform ManagementAutomatticDCVC (Data Collective)Hanwha Asset Management+6 more
Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.
BiotechDeep TechHardwareMedical Devices
Matthew Kellinger(Founder)Michael Previte(Founder)Molly He(Founder)
Co-investorsDraper AssociatesFusionRA CapitalTSVCVenrockWellington Management
Everlywell offers at-home lab testing kits and virtual healthcare services across multiple wellness categories including daily health screening, digestive analysis, sexual health testing, and hormone monitoring.
ConsumerDigital HealthHealthtechWellness & Fitness
Julia Cheek(Founder & CEO)in
Co-investorsAnsa CapitalBreyer CapitalCerity Partners VenturesHalogen Ventures Management Company LlcLux CapitalNext Coast Ventures+12 more
Evidence is a browser-based IDE for building interactive data dashboards and reports using SQL and markdown, with AI-powered development tools and support for multiple database backends.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareToronto, CA
Adam McAskill(Founder)inSean Hughes(Founder)inUdesh Senaratne(Engineer)Archie Wood(Head of Community)Brian Donald(Engineer)Charles Hardy(Engineer)
Co-investorsA.Capital VenturesY CombinatorASDF VenturesNextView VenturesNVP CapitalSV Angel
Co-investorsCivilization Ventures Management, LlcDCVC (Data Collective)Molten VenturesRising TideStart Capital
Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOakland, US
Martin Reese(Co-Founder, President, and CEO)inMartin Reese, Ph.D.(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)in
Co-investorsArtis VenturesMighty CapitalRoche Venture FundCasdin Capital
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.
BiotechHealthtechSan Francisco, US
Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)inK. Peony Yu(Executive Officer)inPat Cotroneo(Executive Officer)inRory Riggs(Founder)
BoardRory B. Riggs(Director)
Co-investorsAvalon BioVenturesRidgeback CapitalScientia VenturesMaverick Ventures
FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.
Digital HealthHealthtechBoston, US
A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)inLiana M Guzman Weis(Executive Officer, Director)
BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in
Co-investors7wire VenturesBessemer Venture PartnersCorewell Health VenturesDefine VenturesHabitat PartnersSeae Ventures+2 more
Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types.
BiotechDigital HealthHealthtechBoulder, US
Ash Alizadeh(Founder)David Kurtz(Founder)Jake Chabon(Founder)Maximilian Diehn(Founder)
Co-investorsAgent CapitalBoulder VenturesCivilization Ventures Management, LlcCU Healthcare Innovation FundPear VC
Galileo operates a medical practice combining a technology platform with in-house primary and multi-specialty clinicians to provide accessible, lower-cost care.
Digital HealthHealthtech
Tom X Lee(Founder)inTom Lee(CEO)
Co-investors8VCGaingelsLifeforce CapitalMcKesson VenturesNat TurnerNext Coast Ventures+8 more
__Twitter.png)
Splunk Agent Observability is a platform that monitors and secures AI agents in production by combining evaluation, observability, cost tracking, and guardrails.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaS
Vikram Chatterji(Founder)inAtindriyo Sanyal(Founder)inYash Sheth(Founder)inClay Wilkes(Founder)Dave Wilkes(Founder)
Co-investorsBattery VenturesCategory VenturesFPVPremji InvestS VenturesScale Venture Partners+10 more
GeekWire is a technology news and media company that covers the tech industry with a focus on the Seattle region and broader startup ecosystem.
Enterprise SoftwareMedia & EntertainmentSeattle, US
John Cook(Founder)Todd Bishop(Founder)Jonathan Sposato(Founder)John C. Cook(Founder)
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsAtlas VentureWellington ManagementCasdin CapitalDeerfield Management CompanyF-Prime CapitalFidelity Investments+1 more
BGI (Huada) is a genomics research and services organization offering clinical genetic testing, scientific research services, forensic/judicial testing, and sequencing instruments.
BiotechDeep TechDigital Health
Wang Jian(Founder)
Co-investorsF-Prime CapitalGreen Pine Capital Partners
Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.
AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB
Peter Donnelly(Founder)inDr Chris Spencer(Founder)Dr Gerton Lunter(Founder)Gilean McVean(Founder)Professor Gil McVean(Founder)Professor Sir Peter Donnelly(Founder)
Co-investorsF-Prime CapitalOxford Science EnterprisesSalica InvestmentsIP Group
Glitzi is a service marketplace platform in Mexico that connects users with beauty and wellness professionals for on-demand services including hairstyling, massage, and facials.
ConsumerMarketplacesMexico City, MX
Ana Ramos(Founder)inLuis Enrique Vazquez(Founder)in
Co-investorsGaingelsY CombinatorAct One VenturesBeagle VenturesGanas VenturesGoodwater Capital+4 more
Google operates the dominant web search engine and its advertising business, alongside Android, YouTube, Google Cloud and the Gemini AI models.
AI & Machine LearningMountain View, US
Larry Page(Founder)Sergey Brin(Founder)Sundar PichaiinOmar Hamoui(Founder)Dick Costolo(Founder)Aamir Virani(Founder)
Co-investorsKleiner PerkinsSilver Lake PartnersSV AngelWestern Technology Investment83NorthAccel+9 more
US direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.
Jack Abraham(Founder)inAndrew Dudum(Founder)Hilary Coles(Founder)Joe Spector(Founder)
Co-investors7GC & Co8VCA-Rod CorpAtomicBeta CapitalBling Capital+24 more
Identifeye provides a fundus imaging platform combining a portable camera device and cloud-based portal software for retinal screening in point-of-care settings.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investorsDecheng CapitalvenBio Partners
BiotechBoulder, US
Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)Kevin Ness(Founder)inRyan Gill(Founder)
Co-investorsiGlobe PartnersKorysOak HC/FTOMX VenturesPaladin Capital GroupSpruce Capital Partners+4 more
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardRobert Nelsen(Director)Vijay Pande(Director)in
Co-investorsAndreessen HorowitzARCH Venture PartnersDeviation CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+9 more
Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.
BiotechBoston, US
James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)
Co-investorsBay City CapitalCloudStone CapitalCycad Group LLCMarkerNXT VenturesAlta Partners+3 more
Ivantis was a medical device company founded in 2007 in Irvine, California, that developed the Hydrus Microstent, a minimally invasive device for treating glaucoma during cataract surgery.
Irvine, US
David Van Meter(Executive Officer, Director)
BoardTara Butler(Director)Douglas Roeder(Director)Ali Behbahani(Director)inRandy Alexander(Director)Thong Yuen Poon(Director)
Co-investorsAscension VenturesRA CapitalMemorialCare Innovation FundNew Enterprise Associates (NEA)
Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease.
BiotechHealthtech
Co-investorsFrazier Life Sciences
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsAvoro Capital AdvisorsHEALTHCARE ROYALTY PARTNERSRA Capital
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical DevicesSan Diego, US
Robert Hoffman(Founder; CEO & Head of Research)Craig Murphy, PhD(Founder; Chief Scientific Officer)Chris LeMasters, MBA(Founder; Executive Board Chairman)
Co-investorsNextech InvestAlexandriaLilly Asia VenturesLongwood Fund
Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.
BiotechHealthtechCambridge, US
Wenru Song(Founder)in
Co-investorsQuan CapitalVivo CapitalIkarian Capital
Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.
FintechSaaS
Anil Stocker(Founder)inCharles Delingpole(Founder)Ilya Kondrashov(Founder)
Co-investorsHolland CapitalMouro CapitalNorthzoneBluebird VenturesJDRF T1D FundNarya Capital+3 more
Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.
BiotechHealthtechMorrisville, US
Roger Jeffs(Co-Founder and Vice Chairman)inFraser Wright(Scientific Co-Founder and Chief Gene Therapy Officer)inShankar Ramaswamy(Founder)inMichele Stone(Chief Scientific Officer)inKatherine Eade(Chief Legal Officer)Britt Petty(Chief Manufacturing Officer)in
Co-investorsPatient Square CapitalPremji InvestAlumni VenturesAmplo VenturesAnjostBluebird Ventures+3 more
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Allen Chao(Founder)
Co-investorsAisling CapitalARCH Venture PartnersMESA VERDE VENTURE PARTNERSProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURES+2 more
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in
Co-investors5AM VenturesAccess BiotechnologyAscenta CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos Expeditions+7 more
Lightdash is an open-source business intelligence tool that natively supports dbt metrics and analytics workflows.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareLondon, GB
Hamzah Chaudhary(Founder)inOliver Laslett(Founder)inJose Rego(Software Engineer)
Co-investorsAccelMoonfire VenturesOutlier GroveY CombinatorAccuro TrusteesCharles Delingpole+5 more
Lovage automatically generates and posts social media content about open appointment slots for beauty professionals, helping them convert availability into client bookings using AI-generated designs.
AI & Machine LearningEnterprise SoftwareMarketing TechSaaSOrem, US
Austin Petersen(Founder)inRobert Hinckley(Founder)inAlexander Steffen(Founder)inBoyd Christiansen
Co-investorsCampus Founders FundY CombinatorAmino CapitalConvoi VenturesD Global VenturesKindling Capital+3 more
Lucira Health manufactures portable diagnostic devices that connect to smartphones to test bodily fluids for infectious diseases, enabling rapid results outside of clinical settings.
BiotechHealthtechMedical DevicesEmeryville, US
Debkishore Mitra(Founder)inJohn R. Waldeisen(Director)John Waldeisen(CEO)Ivan Dimov
BoardErik T. Engelson(Executive Officer, Director)Justin Butler(Director)
Co-investors11.2 CapitalShangBay Capital LLCY CombinatorDCVC (Data Collective)DHVCEclipse Ventures+4 more
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)
Co-investorsARCH Venture PartnersvenBio Partners8VCAxial VC
Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.
Co-investorsARCH Venture PartnersAxial VC
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Founder)inJanice Chen(Founder)inLucas Harrington(Founder)inAshley Tehranchi(Founder)in
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCalifornia Innovation FundDecheng CapitalMayfield FundMission Bay Capital+12 more
MIDI develops digital health solutions for patients and clinicians to improve access to and delivery of care across diverse populations.
Digital HealthHealthtechLos Altos Hills, US
Joanna Stober(Executive Officer, Director)Sharon Meers(President & Co-founder)inJoanna Strober(Founder)inKathleen Jordan MD(Chief Medical Officer & Co-founder)inKathleen Jordan(Founder)
BoardAllison Gates(Director)in
Co-investors1843 Capital25MadisonAble PartnersAdvance Venture PartnersAvestria VenturesCity Light+19 more
Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.
BiotechFemTechHealthtechSouth San Francisco, US
Maneesh Jain(Founder)inStephen Quake(Founder)
BoardLisa Iverson(Director)Ursheet Parikh(Director)inMin Cui(Director)inSamir Kaul(Director)in
Co-investorsCorrelation VenturesDecheng CapitalGaingelsGeneral CatalystGV (Google Ventures)Mayfield Fund+3 more
MyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
BiotechDigital HealthHealthtechMedical Devices
Akash Kumar(Chief Medical and Scientific Officer / Co-Founder)inKate Im(Senior Vice President of Research / Co-Founder)in
Co-investorsHOF CapitalSamsung NextSequoia Capital
Mythic Therapeutics was a clinical-stage biotech developing next-generation antibody-drug conjugates for cancer using its proprietary FateControl technology.
BiotechWaltham, US
Brian Fiske(Executive Officer, Director)George Eliades(Executive Officer, Director)inSandra Poole(Executive Officer)inAlex Nichols(Executive Officer, Director, Promoter)
BoardBryan Roberts(Director)inPeter Hecht(Director)
Co-investorsHemi Ventures, LlcLifeforce CapitalNat TurnerViking GlobalRefactor Capital
NanoString (part of Bruker Spatial Biology) develops instruments and assays for spatial biology and gene expression analysis, including single-cell and subcellular spatial transcriptomics, proteomics, and multiomics.
BiotechDeep TechHealthtechMedical Devices
Co-investorsAspect VenturesKicker VenturesOwl Capital
Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.
AI & Machine LearningBiotechHealthtech
Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)inPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in
Co-investorsVersant VenturesSixty Degree CapitalCowen Healthcare InvestmentsGoldman SachsSection 32
Novavax develops protein-based nanoparticle vaccines paired with its Matrix-M adjuvant to produce broad, long-lasting immune responses.
BiotechHealthtech
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)inMark Goldsmith(Director)
Co-investorsBain Capital Life SciencesEcoR1 CapitalGeneral AtlanticSofinnova VenturesThe Column GroupWellington Management+1 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPGlobal BioAccess FundGreatPoint Ventures+9 more
Oncology Ventures is a cancer-focused venture capital fund that invests in healthcare technology startups related to oncology care.
AI & Machine LearningBiotechDigital HealthHealthtech
Ben Freeberg(Founder, Managing Partner)inJay Freeberg(Chief Financial Officer)
Co-investorsSandwich CapitalAlleyCorpCanaan PartnersConcord Health PartnersCVS Health VenturesForbion+5 more
Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.
BiotechHealthtechMedical DevicesYardley, US
Per Djupesland(Executive Officer, Director)inMichele Janis(Executive Officer)Peter Miller(Executive Officer, Director)inTerrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)in
BoardKlaas De Boer(Director)
Co-investorsAvistaMVM Life Science Partners
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalUCL Technology Fund4BIO CapitalAgent CapitalBaillie Gifford+3 more
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsCurative VenturesNextech InvestRidgeback CapitalThe Column GroupVida Ventures
Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.
BiotechHealthtech
Co-investorsBain Capital Life SciencesGeneral AtlanticKurma PartnersvenBio PartnersViking Global
PicnicAI develops AI technology to support patient-centered clinical care and medical research.
AI & Machine LearningDigital HealthHealthtechSan Francisco, US
Noga Leviner(CEO)inTroy Astorino(CTO)inLuna Federici(Chief Executive Officer)inJustin Maslin(Software Engineer)Shannah Metz(Recruiter)Stephanie Iannello(Recruiting)
Co-investorsY CombinatorAmplify PartnersB Capital GroupFelicis VenturesGreat Oaks Venture CapitalMantis Capital+6 more
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsQuan CapitalRA CapitalLAVOrbiMedVenrock
Propeller Bio discovers and develops biologic therapeutics that target multiple disease-driving pathways to achieve synergistic effects, aimed at patients with unmet medical needs.
BiotechSan Francisco Bay Area, US
David W. Shen(Founder)in
Co-investorsOrbiMedBlackbird VenturesMcKesson VenturesSequoia Capital
Puma Biotechnology is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for cancer treatment.
BiotechHealthtech
Quantum-Si develops next-generation protein sequencing technology that enables single amino acid detection by combining biology, chemistry, artificial intelligence, and semiconductor technology.
BiotechDeep TechHardwareMedical Devices
Jeff Hawkins(CEO)inJeff Keyes(Chief Financial Officer)inChristian LaPointe(General Counsel)inTodd Rearick(Chief Technology Officer)inLindsay Thompson(Chief Human Resources Officer)in
Co-investorsHighCape CapitalYuanBio Venture Capital
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.
BiotechHealthtech
Co-investorsFrazier Life SciencesGV (Google Ventures)Kleiner PerkinsMedicxiSolasta VenturesThe Column Group+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Allergen ResearchFl2021-001Interline Therapeutics, Inc.Spear Bio89 Bio, Inc. (Alumni)Abdera TherapeuticsAcceleron PharmaAduro BiotechAllogene (Alumni)AudentesAvanir PharmaceuticalsAveXisBellicum PharmaceuticalsBiodelivery Sciences International CopyBioDelivery Sciences International, Inc. (Alumni)Biohaven PharmaceuticalCentessa Pharmaceuticals (Alumni)CopyDetect, Inc.Dyax CorpEngene Holdings IncEpizyme, Inc. (Alumni)Generation Bio (Alumni)Ikena Oncology, Inc.ImageneBio, Inc. (Alumni)Immpact Bio UsaImmunomedics, Inc. (Alumni)IndomoInterline TherapeuticsLundbeck Seattle Biopharmaceuticals IncModal Therapeutics Inc.Momenta Pharmaceuticals, Inc. (Alumni)MyokardiaNgm BiopharmaceuticalsObsidian Therapeutics, Inc.OlemaPhaxiam Therapeutics S APopulation Health Investment Co
Browse all 241 investments with full details →
▶41 more tracked companies
Redesign HealthRegulus Therapeutics Inc.Replimune Group, Inc. (Alumni)Rhythm PharmaceuticalsSangamo TherapeuticsSequentaSeraGene TherapeuticsSeranova BioSestina BioSignant HealthSite by GoodlabSlate MedicinesSollis HealthSomaLogicSotera WirelessStackshineStepfulStructure TherapeuticsTassoTenSixteen BioTesseraTesseract HealthThe Medicines CompanyTheseusThird Arc BioThymeThyme CareTP TherapeuticsTurning Point TherapeuticsTurning Point Therapeutics (Alumni)UniqureVeliaVENATORX PHARMACEUTICALS INCVerona PharmaVerve TherapeuticsVignette BioVitae PharmaceuticalsVoyager Therapeutics (Alumni)Xaira TherapeuticsXintheraZenefits
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 93
60 IPOs · 33 acquisitions · showing 74AlumisNASDAQ: ALMSFulcrum TherapeuticsNASDAQ: FULC10x GenomicsNASDAQ: TXGAclaris TherapeuticsNASDAQ: ACRSAdaptimmuneOTC: ADAPYAdaptive BiotechnologiesNASDAQ: ADPTAdicet BioNASDAQ: ACETAlectorNASDAQ: ALECAllogene TherapeuticsNASDAQ: ALLOAlx OncologyNASDAQ: ALXOArbutus Biopharma CorporationNASDAQ: ABUSAura BiosciencesNASDAQ: AURABeam TherapeuticsNASDAQ: BEAMBicara TherapeuticsNASDAQ: BCAXCasi PharmaceuticalsOTC: CASIFCelldex Therapeutics, Inc.NASDAQ: CLDXCG OncologyNASDAQ: CGONCompass TherapeuticsNASDAQ: CMPXCrinetics PharmaceuticalsNASDAQ: CRNXCullinan TherapeuticsNASDAQ: CGEMCytokineticsNASDAQ: CYTKDenali TherapeuticsNASDAQ: DNLIDisc MedicineNASDAQ: IRONEdgewise TherapeuticsNASDAQ: EWTXGH ResearchNASDAQ: GHRSGrailNASDAQ: GRALHinge HealthNYSE: HNGEInsmedNASDAQ: INSMIntellia TherapeuticsNASDAQ: NTLAInvivydNASDAQ: IVVDKeros TherapeuticsNASDAQ: KROSKura OncologyNASDAQ: KURAMadrigalNASDAQ: MDGLMaze TherapeuticsNASDAQ: MAZENateraNASDAQ: NTRAOlema PharmaceuticalsNASDAQ: OLMAOmeros Corp.NASDAQ: OMERParabilis MedicinesNASDAQ: PBLSQuince TherapeuticsNASDAQ: QNCXRelayNASDAQ: RLAYReplimuneNASDAQ: REPLRevolution MedicinesNASDAQ: RVMDRxsightNASDAQ: RXSTScynexisNASDAQ: SCYXSeaport TherapeuticsNASDAQ: SPTXSilence TherapeuticsNASDAQ: SLNSolid BiosciencesNASDAQ: SLDBSUTROVAX, INC.NASDAQ: PCVXSyndax PharmaceuticalsNASDAQ: SNDXTango TherapeuticsNASDAQ: TNGXVaxcyteNASDAQ: PCVXVerastemNASDAQ: VSTMWave Life SciencesNASDAQ: WVEXenon PharmaceuticalsNASDAQ: XENE89 Bio, Inc. (Alumni)acq. by RocheAduro Biotechacq. by Chinook TherapeuticsAmbit Biosciences Corporationacq. by Daiichi SankyoAudentesacq. by Astellas PharmaAvanir Pharmaceuticalsacq. by Otsuka Pharmaceutical Co., Ltd.Bellicum Pharmaceuticalsacq. by The University of Texas MD Anderson Cancer CenterBiohaven Pharmaceuticalacq. by PfizerClipDropacq. by Stability AIDyax Corpacq. by ShireEpizyme, Inc. (Alumni)acq. by Ipsen SAForesight Diagnosticsacq. by NateraGalileoacq. by CiscoImmpact Bio Usaacq. by Lyell Immunopharma, Inc.Immunomedics, Inc. (Alumni)acq. by Gilead SciencesMomenta Pharmaceuticals, Inc. (Alumni)acq. by Johnson & JohnsonMyokardiaacq. by Bristol Myers SquibbNanostringacq. by BrukerNgm Biopharmaceuticalsacq. by The Column GroupPeloton Therapeuticsacq. by MerckRAPT Therapeuticsacq. by GSK
Portfolio news
latest coverage across their companies
Google · techcrunch.com · Sep 30, 2026
Chimagen Biosciences · biospace.com · Sep 15, 2026
Everly Health · forgeglobal.com · Sep 7, 2026
Silence Therapeutics · biospace.com · Sep 2, 2026
Invivyd · investors.invivyd.com · Sep 1, 2026
Vaxcyte · manilatimes.net · Aug 27, 2026
Abcuro · finsmes.com · Aug 18, 2026
IPO stake values · per SEC filings · 8
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| 10x Genomics | 9.6% | $110.00 | Sep 2020 | $804.4M |
| Alumis | 24.4% | $16.00 | Jun 2024 | $202.4M |
| Keros Therapeutics | 6.3% | $50.00 | Nov 2020 | $71.4M |
| Cullinan Therapeutics | 6.0% | $21.00 | Jan 2021 | $53M |
| Maze Therapeutics | 5.3% | $16.00 | Jan 2025 | $37.3M |
| Replimune | 6.5% | $15.00 | Jul 2018 | $30.1M |
| Wave Life Sciences | 6.4% | $16.00 | Nov 2015 | $21.3M |
| Scynexis | 5.0% | $7.70 | Apr 2015 | $5.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2022
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Oct 2020
Disclosed stake · filed Feb 2020
Disclosed stake · filed Feb 2020
Disclosed stake · filed Feb 2019
Disclosed stake · filed Feb 2019
Disclosed stake · filed Feb 2019
Disclosed stake · filed Jan 2019
Disclosed stake · filed Mar 2018
Disclosed stake · filed Feb 2018
19 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Foresite Capital made?
- Foresite Capital has 241 tracked investments, 93 of which have exited, including 15 dated in the last 24 months.
- What stage does Foresite Capital invest at?
- Foresite Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Foresite Capital focus on?
- Foresite Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Foresite Capital located?
- Foresite Capital is headquartered in West Hollywood, US.
- Does Foresite Capital lead rounds?
- Foresite Capital has led 7 of the 38 rounds where its role is on record.
- Who does Foresite Capital co-invest with?
- Foresite Capital most often shares deals with RA Capital, OrbiMed, Avoro Capital Advisors, among 347 tracked co-investors.
- What size deals does Foresite Capital back?
- Across 28 deals with disclosed amounts, Foresite Capital has joined rounds of $22M – $1.2B (median $85M).
From the blog
visit blog ↗Foresite Capital has invested in healthcare innovations across diagnostics, urgent care delivery, and neuropsychiatric drug development, with a focus on companies addressing significant unmet patient needs through differentiated technologies and consumer-driven models. AI summary
Media · Podcasts & interviews
featuring the teamJim Tananbaum, Foresite Capital Founder on Healthcare & Life Sciences
Grace Gong · Jim Tananbaum
How AI Is Rewriting Drug Discovery and Biotech Investing | Jim Tananbaum of Foresite Capital
Nicholas Moran · Jim Tananbaum
Why Jim Tananbaum, Founder & CEO of Foresite Capital, is excited by the Element AVITI
Element Biosciences · Jim Tananbaum
Images
Co-investors · 29
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.
▶17 more co-investors
General AtlanticDeerfield Management CompanySequoia CapitalPontifax Venture CapitalMenlo Ventures5AM VenturesFlare Capital PartnersWestlake Village BioPartnersCivilization Ventures Management, LlcFirst Round CapitalTorch CapitalMolten VenturesBain Capital VenturesWildcat Venture PartnersNorthpond VenturesMaverick CapitalRecode Ventures
Firms observed investing alongside Foresite Capital, from public investor directories. Shared companies are the overlap with Foresite Capital's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
aMoon is a healthcare and life sciences-focused investment firm that partners with scientists and entrepreneurs building companies at the convergence of technology and biology to transform healthcare and accelerate cures.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.